Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript
Summarize this article with:
SA Transcripts157.42K FollowersFollow5ShareSaveComment(1)Play Earnings CallPlay Earnings Call Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH December 19, 2025 8:00 AM EST Company Participants Vipin Garg - President, CEO & DirectorJerome DursoChristophe Arbet-Engels - Chief Medical Officer Conference Call Participants Lee Roth - Burns McClellan, Inc.Yasmeen Rahimi - Piper Sandler & Co., Research DivisionAnnabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research DivisionJonathan Wolleben - Citizens JMP Securities, LLC, Research DivisionMichael DiFiore - Evercore ISI Institutional Equities, Research DivisionPatrick Trucchio - H.C. Wainwright & Co, LLC, Research DivisionCorinne Jenkins - Goldman Sachs Group, Inc., Research DivisionTsan-Yu Hsieh - William Blair & Company L.L.C., Research DivisionWilliam Wood - B. Riley Securities, Inc., Research Division Presentation Operator Good morning, and welcome to the Altimmune conference call. [Operator Instructions]. As a reminder, this call is being recorded. I would now like to turn the call over to Lee Roth, President of Burns McClellan, Investor Relations Adviser to Altimmune. Lee? Lee RothBurns McClellan, Inc. Thanks, operator. As a reminder, a press release summarizing the results of the trial can be found on the Investor Relations section of the company's website. This call is also being recorded, and a copy of the slides and audio will be posted to the IR site at the conclusion of the live event. Following some prepared remarks from management, we'll open the call to your questions. Before we begin, I'd like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For discussions of some of the risks and risk factors that could affect the company's future results and operations, please see the risk factors and